Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T-cell lymphoma Journal Article
| Authors: | Stuver, R.; Horwitz, S. M.; Advani, R. H.; Vose, J. M.; Lee, H. J.; Mehta-Shah, N.; Zain, J. M.; Haverkos, B.; Lechowicz, M. J.; Moskowitz, A. J.; Pham, L. Q.; Leyden, E.; Ansell, S. M.; Lunning, M. A. |
| Article Title: | Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T-cell lymphoma |
| Abstract: | There remains no one standard induction for nodal-based peripheral T-cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1–10 of a 21-day cycle for six cycles of therapy followed by observation, high-dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty-two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2-year progression-free and overall survival were 55% (95% CI 37%–70%) and 78% (95% CI 59%–89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction. © 2023 British Society for Haematology and John Wiley & Sons Ltd. |
| Keywords: | t-cell lymphoma; clinical trials; trials; lymphomas; non-hodgkins lymphoma; malignant lymphomas |
| Journal Title: | British Journal of Haematology |
| Volume: | 202 |
| Issue: | 3 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2023-08-01 |
| Start Page: | 525 |
| End Page: | 529 |
| Language: | English |
| DOI: | 10.1111/bjh.18885 |
| PUBMED: | 37217196 |
| PROVIDER: | scopus |
| PMCID: | PMC11220724 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work